Kymera Therapeutics (KYMR) Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- Wall St futures slide as rising oil, yields dampen mood
- Oil jumps as Middle East supply concerns persist amid shipping attacks
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
| (NASDAQ: KYMR) | Delayed: 108.35 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $108.35 | 52 Week High | $ | |||
| Open | $108.35 | 52 Week Low | $ | |||
| Day High | $108.35 | P/E | N/A | |||
| Day Low | $108.35 | EPS | $ | |||
| Volume | 6,082 | |||||
